Sharon Barr
Overview
Explore the profile of Sharon Barr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
681
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pignolo R, McCarrick-Walmsley R, Wang H, Qiu S, Hunter J, Barr S, et al.
J Bone Miner Res
. 2021 Dec;
37(3):475-483.
PMID: 34954853
Fibrodysplasia ossificans progressiva (FOP) is a progressive, debilitating genetic disease in which skeletal muscle and connective tissue is episodically replaced by heterotopic bone. Discovery of surrogate biomarkers of disease (genotype)-related...
2.
Mateo J, Olmos D, Dumez H, Poondru S, Samberg N, Barr S, et al.
Br J Cancer
. 2016 Mar;
114(8):889-96.
PMID: 27002938
Background: The kinase activity of mTOR involves 2 multiprotein complexes, (mTORC1-mTORC2). Targeting mTORC1 with rapalogues induces compensatory feedback loops resulting in AKT/ERK activation, which may be abrogated by mTORC2 inhibition....
3.
Fang L, Afshar P, Chhibber A, Mohiyuddin M, Fan Y, Mu J, et al.
Genome Biol
. 2015 Sep;
16:197.
PMID: 26381235
SomaticSeq is an accurate somatic mutation detection pipeline implementing a stochastic boosting algorithm to produce highly accurate somatic mutation calls for both single nucleotide variants and small insertions and deletions....
4.
Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models
Cassell A, Freilino M, Lee J, Barr S, Wang L, Panahandeh M, et al.
Neoplasia
. 2012 Dec;
14(11):1005-14.
PMID: 23226094
Head and neck squamous cell carcinoma (HNSCC) is characterized by overexpression of the epidermal growth factor receptor (EGFR) where treatments targeting EGFR have met with limited clinical success. Elucidation of...
5.
Gupta M, Wahner Hendrickson A, Yun S, Han J, Schneider P, Koh B, et al.
Blood
. 2011 Nov;
119(2):476-87.
PMID: 22080480
The mammalian target of rapamycin (mTOR) plays crucial roles in proliferative and antiapoptotic signaling in lymphoid malignancies. Rapamycin analogs, which are allosteric mTOR complex 1 (mTORC1) inhibitors, are active in...
6.
Altman J, Sassano A, Kaur S, Glaser H, Kroczynska B, Redig A, et al.
Clin Cancer Res
. 2011 Mar;
17(13):4378-88.
PMID: 21415215
Purpose: To determine whether mTORC2 and rapamycin-insensitive (RI)-mTORC1 complexes are present in acute myeloid leukemia (AML) cells and to examine the effects of dual mTORC2/mTORC1 inhibition on primitive AML leukemic...
7.
Falcon B, Barr S, Gokhale P, Chou J, Fogarty J, Depeille P, et al.
Cancer Res
. 2011 Mar;
71(5):1573-83.
PMID: 21363918
The mammalian target of rapamycin (mTOR) pathway is implicated widely in cancer pathophysiology. Dual inhibition of the mTOR kinase complexes mTORC1 and mTORC2 decreases tumor xenograft growth in vivo and...
8.
Carayol N, Vakana E, Sassano A, Kaur S, Goussetis D, Glaser H, et al.
Proc Natl Acad Sci U S A
. 2010 Jul;
107(28):12469-74.
PMID: 20616057
mTOR-generated signals play critical roles in growth of leukemic cells by controlling mRNA translation of genes that promote mitogenic responses. Despite extensive work on the functional relevance of rapamycin-sensitive mTORC1...
9.
Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, et al.
Cancer Res
. 2008 Oct;
68(20):8322-32.
PMID: 18922904
Epidermal growth factor receptor (EGFR) and insulin-like growth factor-I receptor (IGF-IR) can cooperate to regulate tumor growth and survival, and synergistic growth inhibition has been reported for combined blockade of...
10.
Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I, et al.
Clin Exp Metastasis
. 2008 Feb;
25(6):685-93.
PMID: 18236164
Over 90% of all cancers are carcinomas, malignancies derived from cells of epithelial origin. As carcinomas progress, these tumors may lose epithelial morphology and acquire mesenchymal characteristics which contribute to...